Medicaments Containing Hormones Market

The global market for medicaments containing hormones but not antibiotics is expected to exhibit growth over the next eight years, with forecasted increases in consumption and production. Despite a slight decrease in 2022, the overall trend shows a prominent increase in both consumption and production since 2012. Key players in the market include China, the United States, and India, with notable growth rates recorded in Nigeria and Bulgaria. Import and export prices have seen fluctuations over the years, with major exporting countries like Ireland and the United States holding significant market shares. Overall, the market is projected to continue expanding, driven by increasing demand worldwide.

Market Forecast

Driven by increasing demand for medicaments containing hormones but not antibiotics worldwide, the market is expected to continue an upward consumption trend over the next eight years. Market performance is forecast to decelerate, expanding with an anticipated CAGR of +4.8% for the period from 2022 to 2030, which is projected to bring the market volume to 584K tons by the end of 2030.

In value terms, the market is forecast to increase with an anticipated CAGR of +6.8% for the period from 2022 to 2030, which is projected to bring the market value to $102.4B (in nominal prices) by the end of 2030.

Consumption

World Consumption of Medicaments Containing Hormones But Not Antibiotics

After three years of growth, consumption of medicaments containing hormones but not antibiotics decreased by -8.2% to 401K tons in 2022. Overall, consumption, however, continues to indicate a prominent increase. Global consumption peaked at 436K tons in 2021, and then dropped in the following year.

The global medicaments containing hormones market size dropped to $60.5B in 2022, falling by -5.8% against the previous year. This figure reflects the total revenues of producers and importers (excluding logistics costs, retail marketing costs, and retailers' margins, which will be included in the final consumer price). Over the period under review, the total consumption indicated a temperate increase from 2012 to 2022: its value increased at an average annual rate of +4.5% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, consumption increased by +29.8% against 2018 indices. Over the period under review, the global market attained the maximum level at $64.2B in 2021, and then contracted in the following year.

Consumption By Country

The countries with the highest volumes of consumption in 2022 were China (62K tons), the United States (48K tons) and India (25K tons), with a combined 34% share of global consumption. Japan, Pakistan, Nigeria, Mexico, Russia, Bangladesh, Germany, Indonesia, Brazil and Turkey lagged somewhat behind, together accounting for a further 33%.

From 2012 to 2022, the most notable rate of growth in terms of consumption, amongst the leading consuming countries, was attained by Nigeria (with a CAGR of +13.3%), while consumption for the other global leaders experienced more modest paces of growth.

In value terms, the largest medicaments containing hormones markets worldwide were Japan ($15.8B), the United States ($14.3B) and Brazil ($2.3B), together accounting for 54% of the global market.

The United States, with a CAGR of +18.3%, saw the highest growth rate of market size in terms of the main consuming countries over the period under review, while market for the other global leaders experienced more modest paces of growth.

The countries with the highest levels of medicaments containing hormones per capita consumption in 2022 were Germany (146 kg per 1000 persons), Japan (144 kg per 1000 persons) and the United States (142 kg per 1000 persons).

From 2012 to 2022, the most notable rate of growth in terms of consumption, amongst the leading consuming countries, was attained by the United States (with a CAGR of +12.2%), while consumption for the other global leaders experienced more modest paces of growth.

Production

World Production of Medicaments Containing Hormones But Not Antibiotics

In 2022, production of medicaments containing hormones but not antibiotics decreased by -8.7% to 398K tons for the first time since 2018, thus ending a three-year rising trend. In general, production, however, posted strong growth. The most prominent rate of growth was recorded in 2015 with an increase of 54%. Over the period under review, global production attained the peak volume at 436K tons in 2021, and then contracted in the following year.

In value terms, medicaments containing hormones production shrank to $66.2B in 2022 estimated in export price. Over the period under review, the total production indicated a perceptible increase from 2012 to 2022: its value increased at an average annual rate of +3.7% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, production increased by +3.1% against 2020 indices. The pace of growth was the most pronounced in 2015 with an increase of 36% against the previous year. Global production peaked at $92.7B in 2017; however, from 2018 to 2022, production failed to regain momentum.

Production By Country

The countries with the highest volumes of production in 2022 were China (62K tons), the United States (48K tons) and India (25K tons), with a combined 34% share of global production. Pakistan, Japan, Nigeria, Mexico, Russia, Bangladesh, Indonesia, Germany, Brazil and Turkey lagged somewhat behind, together accounting for a further 34%.

From 2012 to 2022, the most notable rate of growth in terms of production, amongst the key producing countries, was attained by Nigeria (with a CAGR of +13.3%), while production for the other global leaders experienced more modest paces of growth.

Imports

World Imports of Medicaments Containing Hormones But Not Antibiotics

In 2022, approx. 15K tons of medicaments containing hormones but not antibiotics were imported worldwide; jumping by 21% on 2021. In general, imports, however, recorded a slight setback. Global imports peaked at 20K tons in 2017; however, from 2018 to 2022, imports remained at a lower figure.

In value terms, medicaments containing hormones imports expanded notably to $931M in 2022. Overall, imports showed a measured expansion. The pace of growth was the most pronounced in 2020 when imports increased by 111% against the previous year. As a result, imports attained the peak of $1.6B. From 2021 to 2022, the growth of global imports remained at a lower figure.

Imports By Country

Namibia (2,701 tons), Afghanistan (1,992 tons), the Netherlands (1,443 tons), Spain (1,224 tons), Denmark (863 tons), the United Arab Emirates (627 tons), Hungary (606 tons), the United States (535 tons), Poland (502 tons), Malaysia (404 tons), Qatar (384 tons) and Bulgaria (344 tons) represented roughly 75% of total imports in 2022. Bahrain (301 tons) took a little share of total imports.

From 2012 to 2022, the most notable rate of growth in terms of purchases, amongst the main importing countries, was attained by Bulgaria (with a CAGR of +120.8%), while imports for the other global leaders experienced more modest paces of growth.

In value terms, the largest medicaments containing hormones importing markets worldwide were Denmark ($173M), the United States ($123M) and the Netherlands ($87M), together accounting for 41% of global imports. Poland, Namibia, Hungary, Bulgaria, Spain, the United Arab Emirates, Afghanistan, Qatar, Malaysia and Bahrain lagged somewhat behind, together comprising a further 26%.

Among the main importing countries, Bulgaria, with a CAGR of +143.3%, recorded the highest growth rate of the value of imports, over the period under review, while purchases for the other global leaders experienced more modest paces of growth.

Import Prices By Country

In 2022, the average medicaments containing hormones import price amounted to $60,473 per ton, declining by -8.6% against the previous year. In general, the import price, however, recorded a notable expansion. The growth pace was the most rapid in 2020 an increase of 92%. As a result, import price attained the peak level of $103,528 per ton. From 2021 to 2022, the average import prices failed to regain momentum.

There were significant differences in the average prices amongst the major importing countries. In 2022, amid the top importers, the country with the highest price was the United States ($229,058 per ton), while Bahrain ($2,930 per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Poland (+12.1%), while the other global leaders experienced more modest paces of growth.

Exports

World Exports of Medicaments Containing Hormones But Not Antibiotics

In 2022, overseas shipments of medicaments containing hormones but not antibiotics increased by 4% to 13K tons, rising for the fourth consecutive year after five years of decline. Over the period under review, exports, however, saw a perceptible decrease. The most prominent rate of growth was recorded in 2021 with an increase of 15%. The global exports peaked at 19K tons in 2013; however, from 2014 to 2022, the exports failed to regain momentum.

In value terms, medicaments containing hormones exports surged to $2.5B in 2022. Overall, exports, however, continue to indicate a relatively flat trend pattern. Over the period under review, the global exports hit record highs at $3.2B in 2013; however, from 2014 to 2022, the exports remained at a lower figure.

Exports By Country

In 2022, Pakistan (2.7K tons), Kuwait (2K tons), Denmark (1.6K tons), the United States (1.3K tons) and Indonesia (1.2K tons) was the key exporter of medicaments containing hormones but not antibiotics in the world, constituting 69% of total export. It was distantly followed by the Netherlands (603 tons), committing a 4.7% share of total exports. Spain (446 tons), Ireland (392 tons), the UK (350 tons), Cyprus (320 tons), Poland (290 tons) and Romania (260 tons) took a little share of total exports.

From 2012 to 2022, the most notable rate of growth in terms of shipments, amongst the main exporting countries, was attained by Romania (with a CAGR of +118.2%), while the other global leaders experienced more modest paces of growth.

In value terms, Ireland ($1.7B) emerged as the largest medicaments containing hormones supplier worldwide, comprising 69% of global exports. The second position in the ranking was taken by the United States ($270M), with an 11% share of global exports. It was followed by Denmark, with a 4.1% share.

From 2012 to 2022, the average annual rate of growth in terms of value in Ireland stood at +60.7%. The remaining exporting countries recorded the following average annual rates of exports growth: the United States (+1.2% per year) and Denmark (+14.6% per year).

Export Prices By Country

The average medicaments containing hormones export price stood at $193,107 per ton in 2022, picking up by 247% against the previous year. Overall, the export price posted a moderate increase. As a result, the export price attained the peak level and is likely to continue growth in the immediate term.

There were significant differences in the average prices amongst the major exporting countries. In 2022, amid the top suppliers, the country with the highest price was Ireland ($4,388,518 per ton), while Pakistan ($5,514 per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by Ireland (+57.1%), while the other global leaders experienced more modest paces of growth.

Source: IndexBox Market Intelligence Platform